secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evommune, Inc. (EVMN)
CIK:        0002044725
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001193125-26-093920
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evommune reports Q4/FY2025 net loss $28.3M/$68.9M; positive EVO301 Ph2a data; $125M raise
--------------------------------------------------------------------------------

- Q4 net loss $28.3M; FY net loss $68.9M vs $66.8M prior year. Revenue $13.0M FY (Maruho deal). Cash $216.7M at Dec 31, 2025.
- Positive Phase 2a POC data for EVO301 in atopic dermatitis: met primary endpoint, 33% placebo-adjusted EASI reduction at week 12 after 2 doses.
- EVO756 Phase 2b top-line data expected 2Q26 for CSU, 2H26 for AD; Phase 2b in migraine to start mid-2026.
- Closed $125M private placement in Feb 2026; cash runway extended through 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2044725/000119312526093920/0001193125-26-093920-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2044725/000119312526093920/evmn-20260305.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-093920

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer